Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Vital Therapies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Vital Therapies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vital Therapies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Vital Therapies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Vital Therapies's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Vital Therapies's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Vital Therapies is high growth as no earnings estimate data is available.
Unable to determine if Vital Therapies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Vital Therapies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Duane D. Nash, M.D., J.D., M.B.A. has been the President of Vital Therapies, Inc. since March 08, 2016 and has been its Chief Executive Officer and Director since January 26, 2019. Dr. Nash served as the Chief Business Officer at Vital Therapies, Inc. from March 19, 2012 to March 8, 2016 and also served as its Executive Vice President from May 2013 to March 2016. He served as Medical Director at Vital Therapies, Inc. from March 19, 2012 to May 2013. He served as Senior Vice President in Equity Research at Wedbush PacGrow Life Sciences. He served as Senior Vice President at Wedbush Securities Inc., Research Division from March 2009 to March 2012. He used to cover cardiac, hepatic and regenerative medicines at the firm. He was a Healthcare Research Analyst at Pacific Growth Equities, LLC, Research Division from April 2008 through March 2009. He was an Independent Director of Akebia Therapeutics, Inc. since May 2013 until December 12, 2018. He served as a Director of Aerpio Pharmaceuticals, Inc. (formerly Aerpio Therapeutics, Inc.) from September 2012 to March 2017. He has practiced as an Attorney from November 2002 to February 2008. He was employed at Davis Polk & Wardwell LLP, where he practiced intellectual property litigation, as well as patent evaluation and strategy in the merger and acquisition context. He worked at two other Bay Area law firms and also completed his internship in General Surgery at the University of California at San Francisco, where he served as a member of the liver transplant team. According to STARMINE and Thomson Reuters, Dr. Nash is ranked first among 66 equity research analysts nationwide who publish in the biotechnology market, based on prior 12 month return on recommendations. He is a California-licensed Physician at Medical Board of California and also an inactive member of the California Bar. Dr. Nash holds his J.D. from the University of California at Berkeley, his M.D. from Dartmouth Medical School, an M.B.A. from the University of Oxford and a B.A. in Biology from Williams College.
Duane's compensation has been consistent with company performance over the past year.
Duane's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Vital Therapies management team is about average.
CEO, President & Director
Executive VP & Chief Scientific Officer
General Counsel & Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Vital Therapies board of directors is less than 3 years, this suggests a new board.
Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is based in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.